Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
16.64
+2.04 (13.97%)
At close: Oct 13, 2025, 4:00 PM EDT
16.69
+0.05 (0.30%)
After-hours: Oct 13, 2025, 5:50 PM EDT
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $160.00M in the quarter ending June 30, 2025, with 310.26% growth. This brings the company's revenue in the last twelve months to $262.00M, up 6.07% year-over-year. In the year 2024, Arcus Biosciences had annual revenue of $258.00M with 120.51% growth.
Revenue (ttm)
$262.00M
Revenue Growth
+6.07%
P/S Ratio
5.40
Revenue / Employee
$417,863
Employees
627
Market Cap
1.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RCUS News
- 1 day ago - Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study - Business Wire
- 4 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 days ago - Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 days ago - Why Is Arcus Biosciences Stock Trading Higher On Monday? - Benzinga
- 7 days ago - Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event - Business Wire
- 4 weeks ago - Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation - Business Wire